SciSparc Ltd. (NasdaqCM: SPRC)
Health Care · Pharmaceuticals · IL
$4.43
-0.89% today · -87.6% 1Y
SciSparc Ltd. (NasdaqCM: SPRC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.60M and employs 3 people.
Over the last twelve months the share price has lost 87.6%, trading between 2.98 and 43.65.
Tweenvest scores SciSparc Ltd. across four factors: quality 36/100, value 39/100. Its strongest factor is value.
SPRC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.60M
- Revenue (TTM)
- $679.00K
- P/E
- —
- EPS
- -22.11
- Dividend yield
- —
- Beta (5Y)
- 2.55
- 52-week high
- $43.65
- 52-week low
- $2.98
- Avg volume (3M)
- —
- Shares outstanding
- 580.97K
- Employees
- 3
- Next earnings
- —
About SciSparc Ltd.
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
- ISIN
- IL0010951403
- Founded
- 2004
- Listed since
- Aug 30, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Clearmind Medicine Inc.NasdaqCM: CMND | $2.77M | $6.83 | +3.80% |
| Lasa Supergenerics LimitedNSEI: LASA | $2.77M | Rs5.32 | -5.00% |
| Nexalis Therapeutics LimitedASX: NX1 | $2.67M | AU$— | — |
| IM Cannabis Corp.NasdaqCM: IMCC | $2.60M | $1.46 | -7.91% |
| XORTX Therapeutics Inc.NasdaqCM: XRTX | $2.56M | $1.74 | +23.40% |
| Welcure Drugs and Pharmaceuticals LimitedBSE: 524661 | $2.55M | Rs0.20 | -4.76% |
| Argent BioPharma LimitedASX: RGT | $2.55M | AU$0.03 | +3.33% |
| Cai Lay Veterinary Pharmaceutical Joint Stock CompanyHNX: MKV | $2.54M | ₫13,200.00 | +10.00% |
Figures last refreshed Oct 11, 2026.